Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Continues To Make Progress In Big Potential Markets Despite Stock Weakness

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2019 Results - Earnings Call Transcript

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2019 Results - Earnings Call Transcript

Shares of Aldeyra Therapeutics Inc., a thinly traded micro-cap biotech, plummeted Tuesday morning.

No Solace For Aldeyra As Late-Stage Study Of Lead Drug In Anterior Uveitis Fails

Aldeyra Therapeutics Inc. shares  were down 29% in premarket trade Tuesday, after the company said a trial of a treatment for uveitis, or inflammation of the eye, failed to meet its main goals.

Aldeyra shares slide 29% premarket after trial of eye disease treatment fails to meet goals

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q1 2019 Results - Earnings Call Transcript

Aldeyra (ALDX) announced positive top-line data from a phase III study on pipeline product, reproxalap topical ophthalmic solution in patients with allergic conjunctivitis.

Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge

The small-cap pharma announced positive results from a phase 3 trial.

Here's Why Aldeyra Therapeutics Stock Soared as Much as 79.1% Today

News for Aldeyra Therapeutics Stock (ALDX)